Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug
Administration. It can bind to the amino acid residues of the 26S proteasome, thereby …

Background: Bortezomib is a reversible inhibitor of proteasome proteins in mammalian cells.
Bortezomib is proven to be cytotoxic to a number of tumor cells by disrupting their normal …

The establishment of more effective treatments that can circumvent chemoresistance in
Multiple Myeloma (MM) is a priority. Although bortezomib (BTZ) is one of the most potent …

Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the
treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib …

Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits
the ubiquitin proteasome pathway that leads to the degradation of many intracellular …

Proteasome inhibition is a validated therapeutic strategy for the treatment of B-cell
neoplasms. The peptide boronate based inhibitor bortezomib has become an important tool …

Tumor growth is associated with elevated proteasome expression and activity. This makes
proteasomes a promising target for antitumor drugs. Current antitumor drugs such as …

Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the
treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as …

The ubiquitin-proteasome pathway regulates many basic cellular processes and has been
proven to be a promising target for cancer therapy. Bortezomib is the first US Food and Drug …

The proteasome is a multi-unit enzyme complex found in the cytoplasm and nucleus of all
eukaryotic cells and is responsible for degradation of unneeded or damaged intracellular …